InvestorsHub Logo
Followers 14
Posts 1735
Boards Moderated 0
Alias Born 01/21/2014

Re: barnstormer post# 31865

Friday, 03/27/2015 3:45:52 PM

Friday, March 27, 2015 3:45:52 PM

Post# of 690801
Dumb tweet interesting article;

CHAPEL HILL, N.C., March 12, 2015 /PRNewswire/ -- Annias Immunotherapeutics today announced the online publication in Nature of new clinical results demonstrating a dramatic improvement in survival for patients with lethal Glioblastoma multiforme (GBM) brain tumors who were treated with an innovative new cancer vaccine and approach to therapy developed by the company's scientific founder and collaborators at Duke Cancer Institute. The experimental treatment used a tetanus vaccine booster to prime the immune system prior to administration of a therapeutic vaccine targeting a strain of Cytomegalovirus (CMV) that is harbored in many solid tumor types but is not present in healthy surrounding tissues. While patients with glioblastoma rarely survive more than 18 months from diagnosis, most of the 24 patients who received the new immunotherapy in two Phase 1/2 studies lived nearly five years or longer, with the longest survivor still disease-free eight years from diagnosis.


Wow MOST lived 5 years or longer! What does anyone have to say about that? Did anyone see this on CNN, CNBC or so on? No because it is from a Phase I-II and everyone knows they are almost never replicated.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NWBO News